Entering text into the input field will update the search result below

FDA accepts AstraZeneca's marketing application for expanded use of cancer med Lynparza

Oct. 18, 2017 11:52 AM ETAstraZeneca PLC (AZN) StockBy: Douglas W. House, SA News Editor
  • The FDA accepts for review AstraZeneca's (NASDAQ:AZN -0.3%) supplemental New Drug Application (sNDA) seeking approval for PARP inhibitor LYNPARZA (olaparib) for the treatment of patients with BRCA mutation-positive, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy, the first potential indication beyond ovarian cancer.
  • The FDA's action date will be in Q1 2018.

Recommended For You

More Trending News

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC